Anti-OX40 Antibody PF-04518600

Phase 2Biologic

UUniversity of Southern California

Anti-OX40 Antibody PF-04518600 is one of 51 biologic programs targeting Kidney Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerActive, not recruiting

Breast CancerRecruiting

Kidney CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adenocard

Astellas

Preclinical

2 2

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 3

Anti-OX40 Antibody PF-04518600

UUniversity of Southern California

Phase 2

1 4

Duragesic

CCephalon

Preclinical

1 5

Rilvegostomig

AstraZeneca

Preclinical

1 6

Vfend

PPrism Pharmaceuticals

Preclinical

—7

Ablavar

LLantheus Medical Imaging

Preclinical

2 8

4SCAR T Cells

SShenzhen Geno-Immune Medical Institute

Preclinical

1 9

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

1 10

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Kidney Cancer

NCT03092856

Clinical

Trials by Indication[1]

Kidney Cancer1 trial

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

Active, not recruiting·UUniversity of Southern California·Phase 2·NCT03092856·62 enrolled

Breast Cancer1 trial

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting·LLaura Huppert, MD, BA·Phase 2·NCT03971409·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Anti-OX40 Antibody PF-04518600. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-OX40 Antibody PF-04518600 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-OX40 Antibody PF-04518600. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Southern California company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Southern California

Anti-OX40 Antibody PF-04518600

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Kidney Cancer1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News